CR Bard Earns $1.62 Per Share

After the closing bell, CR Bard ($BCR) reported second-quarter earnings of $1.62 per share. The market isn’t pleased as the stock is down about 5% after hours, but I think it’s a decent number. The company had given a range of $1.61 to $1.65 per share and Wall Street was expecting $1.64 per share, so Bard was in the ballpark.

As with other companies this earnings season, Bard is running its business well. The problem is the economy in other parts of the world, especially Europe. Bard’s CEO said:

The economic climate remains challenging, especially in the United States and Europe. Navigating the short term while positioning for the long term is how we have remained strong and successful for over a century. As we have said, we believe the medical device companies who thrive in the future will provide clinically effective products at a value that benefits the entire healthcare system. Our teams are well positioned to identify unmet needs and provide successful solutions for our customers, and we see significant long-term opportunity as we continue to execute on our strategy.

I didn’t see any change in the forecast for this year, or any guidance for Q3. The company had previously said that it sees earnings growing by 3% to 4% for this year. That works out to a range of $6.59 to $6.66 per share for this year. For the first half of the year, Bard has earned $3.23 per share so they’re basically on track to hit those numbers.

Posted by on July 25th, 2012 at 6:14 pm


The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.

Tickers: